• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

突变 D816V 改变了 c-KIT 受体细胞质区域的内部结构和动力学:对二聚化和激活机制的影响。

Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms.

机构信息

LBPA, CNRS-ENS de Cachan, Cachan, France.

出版信息

PLoS Comput Biol. 2011 Jun;7(6):e1002068. doi: 10.1371/journal.pcbi.1002068. Epub 2011 Jun 16.

DOI:10.1371/journal.pcbi.1002068
PMID:21698178
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3116893/
Abstract

The type III receptor tyrosine kinase (RTK) KIT plays a crucial role in the transmission of cellular signals through phosphorylation events that are associated with a switching of the protein conformation between inactive and active states. D816V KIT mutation is associated with various pathologies including mastocytosis and cancers. D816V-mutated KIT is constitutively active, and resistant to treatment with the anti-cancer drug Imatinib. To elucidate the activating molecular mechanism of this mutation, we applied a multi-approach procedure combining molecular dynamics (MD) simulations, normal modes analysis (NMA) and binding site prediction. Multiple 50-ns MD simulations of wild-type KIT and its mutant D816V were recorded using the inactive auto-inhibited structure of the protein, characteristic of type III RTKs. Computed free energy differences enabled us to quantify the impact of D816V on protein stability in the inactive state. We evidenced a local structural alteration of the activation loop (A-loop) upon mutation, and a long-range structural re-organization of the juxta-membrane region (JMR) followed by a weakening of the interaction network with the kinase domain. A thorough normal mode analysis of several MD conformations led to a plausible molecular rationale to propose that JMR is able to depart its auto-inhibitory position more easily in the mutant than in wild-type KIT and is thus able to promote kinase mutant dimerization without the need for extra-cellular ligand binding. Pocket detection at the surface of NMA-displaced conformations finally revealed that detachment of JMR from the kinase domain in the mutant was sufficient to open an access to the catalytic and substrate binding sites.

摘要

III 型受体酪氨酸激酶(RTK)KIT 在通过磷酸化事件传递细胞信号中起着至关重要的作用,这些磷酸化事件与蛋白构象在非活性和活性状态之间的转换有关。D816V KIT 突变与各种病理有关,包括肥大细胞增多症和癌症。D816V 突变的 KIT 是组成型激活的,并且对抗癌药物伊马替尼治疗有抗性。为了阐明这种突变的激活分子机制,我们应用了一种结合分子动力学(MD)模拟、正常模式分析(NMA)和结合位点预测的多方法程序。使用该蛋白的非活性自动抑制结构,对野生型 KIT 和其突变 D816V 进行了 50-ns 的 MD 模拟,该结构是 III 型 RTK 的特征。计算的自由能差异使我们能够量化 D816V 对无活性状态下蛋白稳定性的影响。我们证明了突变后激活环(A 环)的局部结构改变,以及近膜区(JMR)的长程结构重新组织,随后与激酶结构域的相互作用网络减弱。对几种 MD 构象的详细正常模式分析提供了一个合理的分子原理,即提议 JMR 在突变体中比在野生型 KIT 中更容易离开其自动抑制位置,因此能够促进激酶突变体二聚化,而无需额外的细胞外配体结合。在 NMA 位移构象表面的口袋检测最终表明,突变体中 JMR 与激酶结构域的分离足以打开通向催化和底物结合位点的通道。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/91374edde1b5/pcbi.1002068.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/a8c0a9f15078/pcbi.1002068.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/5e192ff78c7d/pcbi.1002068.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/dff462cef102/pcbi.1002068.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/aec5cfc71455/pcbi.1002068.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/b030a8829d99/pcbi.1002068.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/d8bcf50365d3/pcbi.1002068.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/d942bdeffddf/pcbi.1002068.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/faa93d351062/pcbi.1002068.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/91374edde1b5/pcbi.1002068.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/a8c0a9f15078/pcbi.1002068.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/5e192ff78c7d/pcbi.1002068.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/dff462cef102/pcbi.1002068.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/aec5cfc71455/pcbi.1002068.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/b030a8829d99/pcbi.1002068.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/d8bcf50365d3/pcbi.1002068.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/d942bdeffddf/pcbi.1002068.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/faa93d351062/pcbi.1002068.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edca/3116893/91374edde1b5/pcbi.1002068.g009.jpg

相似文献

1
Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms.突变 D816V 改变了 c-KIT 受体细胞质区域的内部结构和动力学:对二聚化和激活机制的影响。
PLoS Comput Biol. 2011 Jun;7(6):e1002068. doi: 10.1371/journal.pcbi.1002068. Epub 2011 Jun 16.
2
Differential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communication.集落刺激因子1受体(CSF-1R)D802V和原癌基因c-KIT D816V同源突变对受体三级结构和变构通讯的差异影响
PLoS One. 2014 May 14;9(5):e97519. doi: 10.1371/journal.pone.0097519. eCollection 2014.
3
Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.与野生型c-kit相比,近膜区突变体V560G Kit对伊马替尼(STI571)更敏感,而激酶结构域突变体D816V Kit则具有抗性。
Mol Cancer Ther. 2002 Oct;1(12):1115-24.
4
A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance.KIT 活性状态和非活性状态之间的动态平衡转变导致了耐药性。
Proteins. 2020 Nov;88(11):1434-1446. doi: 10.1002/prot.25963. Epub 2020 Jun 25.
5
Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance.激活环酪氨酸磷酸化在 c-Kit 自身激活机制中的作用及其在舒尼替尼耐药中的意义。
J Biochem. 2010 Apr;147(4):601-9. doi: 10.1093/jb/mvq015. Epub 2010 Feb 10.
6
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.对甲磺酸伊马替尼耐药的人源c-KIT激活突变对酪氨酸激酶抑制剂PKC412敏感。
Blood. 2005 Jul 15;106(2):721-4. doi: 10.1182/blood-2004-12-4617. Epub 2005 Mar 24.
7
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.达沙替尼(BMS-354825)可抑制KITD816V,这是一种对伊马替尼耐药的激活突变,可引发大多数系统性肥大细胞增多症患者的肿瘤生长。
Blood. 2006 Jul 1;108(1):286-91. doi: 10.1182/blood-2005-10-3969. Epub 2006 Jan 24.
8
KIT D816V is dimerization-independent and activates downstream pathways frequently perturbed in mastocytosis.KIT D816V 是二聚化非依赖性的,并且经常激活肥大细胞病中经常受到干扰的下游途径。
Br J Haematol. 2023 Sep;202(5):960-970. doi: 10.1111/bjh.18116. Epub 2022 Mar 4.
9
Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target.通过合理的药物重新设计克服癌症治疗中的耐药性:伊马替尼——移动靶标
Cancer Res. 2007 May 1;67(9):4028-33. doi: 10.1158/0008-5472.CAN-07-0345.
10
A change in structural integrity of c-Kit mutant D816V causes constitutive signaling.c-Kit突变体D816V的结构完整性变化会导致组成性信号传导。
Mutat Res. 2018 Mar;808:28-38. doi: 10.1016/j.mrfmmm.2018.02.001. Epub 2018 Feb 17.

引用本文的文献

1
Salivary Cystatin D Interactome in Patients with Systemic Mastocytosis: An Exploratory Study.唾液胱抑素 D 在系统性肥大细胞增多症患者中的相互作用组:一项探索性研究。
Int J Mol Sci. 2023 Sep 27;24(19):14613. doi: 10.3390/ijms241914613.
2
Avapritinib for the treatment of KIT mutation-negative systemic mastocytosis.阿伐普替尼用于治疗KIT突变阴性的系统性肥大细胞增多症。
Proc (Bayl Univ Med Cent). 2022 Sep 20;36(1):81-82. doi: 10.1080/08998280.2022.2123661. eCollection 2023.
3
Mutations responsible for the carbapenemase activity of SME-1.导致SME-1碳青霉烯酶活性的突变

本文引用的文献

1
Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives.肥大细胞病的发病机制、分类和治疗:2010 年的最新进展和未来展望。
Expert Rev Hematol. 2010 Aug;3(4):497-516. doi: 10.1586/ehm.10.42.
2
Activation of the edema factor of Bacillus anthracis by calmodulin: evidence of an interplay between the EF-calmodulin interaction and calcium binding.钙调蛋白对炭疽杆菌水肿因子的激活作用:EF-钙调蛋白相互作用与钙结合之间相互作用的证据。
Biophys J. 2010 Oct 6;99(7):2264-72. doi: 10.1016/j.bpj.2010.07.044.
3
Large-scale comparison of four binding site detection algorithms.
RSC Adv. 2022 Aug 15;12(35):22826-22842. doi: 10.1039/d2ra02849b. eCollection 2022 Aug 10.
4
Immunohistochemical Staining to Identify Concomitant Systemic Mastocytosis in Acute Myeloid Leukemia with .免疫组化染色鉴定伴有全身性肥大细胞增多症的急性髓系白血病。
Ann Lab Med. 2022 Nov 1;42(6):678-682. doi: 10.3343/alm.2022.42.6.678.
5
Case Report: Evolution of D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With Rearrangement Responsive to Imatinib.病例报告:D816V 阳性系统性肥大细胞增多症向对伊马替尼敏感的重排性髓系肿瘤的演变
Front Oncol. 2021 Nov 30;11:734025. doi: 10.3389/fonc.2021.734025. eCollection 2021.
6
Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.肥大细胞增多症中遗传和获得性基因突变的临床影响。
Int J Mol Sci. 2021 Jan 2;22(1):411. doi: 10.3390/ijms22010411.
7
Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy.系统性肥大细胞增多症的分子生物学新进展:对诊断、预后和治疗的影响。
Int J Mol Sci. 2020 Jun 2;21(11):3987. doi: 10.3390/ijms21113987.
8
Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap.系统性肥大细胞增多症:遵循酪氨酸激酶抑制路线图
Front Pharmacol. 2020 Apr 14;11:443. doi: 10.3389/fphar.2020.00443. eCollection 2020.
9
The Spectrum of Aggressive Mastocytosis: A Workshop Report and Literature Review.侵袭性肥大细胞增生症的范围:一个研讨会报告和文献回顾。
Pathobiology. 2020;87(1):2-19. doi: 10.1159/000504099. Epub 2019 Dec 4.
10
"Infostery" analysis of short molecular dynamics simulations identifies highly sensitive residues and predicts deleterious mutations.“Infostery”分析短分子动力学模拟确定高度敏感的残基并预测有害突变。
Sci Rep. 2018 Oct 31;8(1):16126. doi: 10.1038/s41598-018-34508-2.
四种结合位点检测算法的大规模比较。
J Chem Inf Model. 2010 Dec 27;50(12):2191-200. doi: 10.1021/ci1000289. Epub 2010 Sep 9.
4
Molecular dynamics simulations and elastic network analysis of protein kinase B (Akt/PKB) inactivation.蛋白激酶 B(Akt/PKB)失活的分子动力学模拟和弹性网络分析。
J Chem Inf Model. 2010 Sep 27;50(9):1602-10. doi: 10.1021/ci100076j.
5
Cell signaling by receptor tyrosine kinases.受体酪氨酸激酶的细胞信号转导。
Cell. 2010 Jun 25;141(7):1117-34. doi: 10.1016/j.cell.2010.06.011.
6
Use of allostery to identify inhibitors of calmodulin-induced activation of Bacillus anthracis edema factor.利用变构作用鉴定钙调蛋白诱导炭疽杆菌水肿因子激活的抑制剂。
Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11277-82. doi: 10.1073/pnas.0914611107. Epub 2010 Jun 7.
7
Consensus modes, a robust description of protein collective motions from multiple-minima normal mode analysis--application to the HIV-1 protease.共识模式,一种从多极值本征模分析中对蛋白质集体运动进行稳健描述的方法——在 HIV-1 蛋白酶中的应用。
Phys Chem Chem Phys. 2010 Mar 28;12(12):2850-9. doi: 10.1039/b919148h. Epub 2010 Feb 1.
8
Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases.受体酪氨酸激酶激活或自身磷酸化中不对称的酪氨酸激酶排列。
Mol Cells. 2010 May;29(5):443-8. doi: 10.1007/s10059-010-0080-5. Epub 2010 Apr 28.
9
Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases.分子动力学模拟表明构象选择控制伊马替尼与几种酪氨酸激酶结合偏好性。
J Biol Chem. 2010 Apr 30;285(18):13807-15. doi: 10.1074/jbc.M110.109660. Epub 2010 Mar 3.
10
Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance.激活环酪氨酸磷酸化在 c-Kit 自身激活机制中的作用及其在舒尼替尼耐药中的意义。
J Biochem. 2010 Apr;147(4):601-9. doi: 10.1093/jb/mvq015. Epub 2010 Feb 10.